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Abstract
Objective: To estimate HIV prevalence among injecting drug users (IDUs) in a drug trafficking
city in southwest Sichuan Province, China.
Methods: A total of 314 IDUs was invited to participate in the cross-sectional survey in 2004
through community outreach recruitment and peer referrals. Blood sample was taken for HIV
antibody testing and a structured questionnaire was administered to collect information on
socio-demographics, drug using and sexual behaviors.
Results: HIV prevalence among IDUs was 17.8% (56/314), about one half higher than that in
previous survey in 2002 (11.3%, 43/379). Yi and other minority ethnicity (Odds ratio [OR], 3.1;
95% confidence interval [CI], 1.7–5.8; P < 0.001), and total times of sharing injecting equipments
1–9 times versus none, OR, 2.7; 95% CI 1.2–6.2; P = 0.02; and ≥10 times versus none, OR, 7.5;
95% CI, 3.2–17.7; P < 0.001) were independent risk factors for HIV infection.
Conclusion: IDUs with high prevalence rates of HIV and equipment sharing behavior in the
drug trafficking city may serve a source for further spread of HIV to other areas in China. The
increasing trend of HIV epidemic among IDUs underscores the urgency of scaling up
interventions.
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Background
Injecting drug use (IDU) has been the most important risk
factor for HIV spread in China. The first HIV outbreak
among IDUs was observed in 1989 in a bordering area in
Southern Yunnan Province [1]; as of 2002, all 31 prov-
inces, municipalities and autonomous regions in main-
land China have reported HIV infection among IDUs [2].
A national epidemiological survey in 16 provinces in
2003 found that, on average, 54% drug users were IDUs
and 7% IDUs were infected with HIV [Chinese Center for
Disease Control, unpublished data]. It is estimated that
about 44.3% of the 650,000 Chinese currently living with
HIV/AIDS are drug users [2]. The relative importance of
IDU in contribution to total reported HIV/AIDS cases has
been declining over years as sexual transmission increases
and HIV screening efforts among former plasma donors
are enhanced; however, IDU is likely to remain as one
major risk as drug use expands from rural bordering areas
in Southwestern China to the whole country, especially to
urban areas [3].
Xichang is a county-level city in Sichuan Province in
Southern China and hosts a population of over 600,000
in total and 380,000 rural residents. The majority of the
residents are Han ethnics and approximate 10% are Yi
minority ethnics. Located on one major drug trafficking
route [4], Xichang City has about 100,000 migrant people
each year and nearly 2,500 registered local drug users. A
community-based cross-sectional survey among 379
IDUs in 2002 found that 11.3% of IDUs in Xichang were
infected with HIV [4], and a subsequent 12-month follow-
up study showed a seroconversion rate of 3.17 per 100
person-years [5]. There are virtually no systemic popula-
tion-based interventions, though some IDUs might
receive research-oriented counseling services and even
fewer participated in methadone maintenance therapy
program which was started in Match 2004. We conducted
this cross-sectional study in 2004 to estimate the trend of
HIV epidemic among IDUs in this drug trafficking area.
Methods
Study design and study population
This cross-sectional study was conducted between May
and July 2004 among IDUs in Xichang City, Sichuan Prov-
ince. Known IDUs in the community were contacted
directly by outreach workers and indirectly through words
of mouth to invite IDUs to join the study. Snowball sam-
pling was also employed as a recruitment strategy. A small
financial incentive was given to participants who success-
fully referred peers to the study. Eligibility criteria
required that participants be at least 18 years old and have
injected drugs at least one time in the past 3 months, be
willing to provide informed consent and give blood spec-
imen for HIV testing, and have not participated in the
cohort study conducted in 2002 [4,5], excluding those
who were already known to have HIV infection before
recruitment. The active injection of drugs was screened by
eligibility questionnaire interview and verified by the
presence of needle marks or medical record. Xichang
Center for STD and Leprosy Control, whereby the study
was conducted, has a database for all HIV-infected local
residents in Xichang City, and a Participant Information
File System (PIFS) software program was developed to
record participants' name, locator information and study
visits for this study as well as for previous cross-sectional
and cohort studies [4,5], so that those who had been
tested HIV-positive and/or had participated in the previ-
ous studies were identified during the eligibility screening
and excluded for this study. After written informed con-
sent was obtained, a structured questionnaire was admin-
istered by trained interviewers to collect information
socio-demographics, drug use and sharing and sexual
behaviors. A blood specimen was collected for testing of
HIV antibody. All study participants were given HIV post-
testing counseling, and those who were HIV positive were
referred to China CARES project in Xichang City which
provides comprehensive community-based HIV/AIDS
services including voluntary testing and counseling, free
antiretroviral therapy and treatment of opportunistic
infections. Study protocol and informed consent were
approved by the institutional review board of the
National Center for AIDS/STD Control and Prevention of
the China Center for Disease Control and Prevention.
Laboratory analyses
Blood specimen was screened for HIV antibody by
enzyme-linked immunosorbent assay (ELISA) (Beijing
Wantai Biologic Medicine Co., China). Positive ELISA
specimen was confirmed by an HIV-1/2 Western Blot
immune assay (HIV Blot 2.2 WB; Genelabs Diagnositics,
Singapore). Samples positive in both tests were consid-
ered HIV-positive.
Statistical analysis
Questionnaire data were double-entered and compared
with Epi Data software (Epi Data 3.1 for Windows; The
Epi Data Association Odense, Denmark). Then, the data
were converted and analyzed using Statistical Analysis
System (SAS 9.1 for Windows; SAS Institute Inc., NC).
Univariate analyses including Chi-square test, Fisher's
exact test, or Mantel-Haenszel chi-square test were per-
formed to evaluate the association of HIV infection with
socio-demographic, drug using and sexual behaviors.
Those variables significant in univariate analyses (P  ≤
0.10) were included in a multivariate logistic regression
model. The final model was constructed by eliminating
non-significant variables in a stepwise manner, identify-
ing variables that were independently associated with HIV
seropositivity.Harm Reduction Journal 2007, 4:6 http://www.harmreductionjournal.com/content/4/1/6
Page 3 of 7
(page number not for citation purposes)
Results
Socio-demographic characteristics, drug using and sexual 
behaviors
A total of 316 IDUs were screened, one person did not
meet eligibility criteria and one person refused to partici-
pate; therefore, 314 subjects were included in the analy-
ses. 247 were referred by seeds or peers (78.7%), others by
outreach workers. The average age was 29 (range 18–46)
years; 85.7% were males; 38.8% were Yi or other minority
ethnics. Education distribution was illiteracy (14.6%),
primary school (23.6%) and junior high school (44.9%).
About half (49.4%) were never married, and 23.6% were
divorced. 61.2% of subjects were unemployed and 26.0%
owned a house.
The average age of beginning to use drugs, injecting drugs
and sharing injection equipments (including needles or
syringes) were 22, 25 and 26 years, respectively. In the
past 3 months, 64.3% used heroin as frequently as ≥7
times per week. Of all subjects, 62.7% reported a history
of sharing equipments. Reasons for sharing equipments
included: "do not know where to obtain", "inconvenient
to obtain", and "high price of syringes and needles." Fifty-
nine percent of subjects reported having heterosexual
activities and none having same-sex contacts in the past
six months, and 24.2% had new sex partners; 20.4% gave
money for sex and 7.3% received money for sex. Among
67 subjects who had casual and/or commercial sexual
partners in the last month, 10.5% reported using con-
doms consistently.
HIV prevalence and risk factors
Of 314 participants, 56 (17.8%) were infected with HIV.
In univariate analyses, factors significantly associated with
HIV infection at a level of 0.10 are sex, marital status, eth-
nicity, total times of sharing injecting equipments in the
past, total number of partners sharing injecting equip-
ments in the past, having new partners sharing injecting
equipments in last 3 months, sharing needles and
syringes, rinse water, and cookers in the last 3 months,
having heterosexual intercourses and not having a pri-
mary sexual partner in the last 6 months (Table 1, 2, 3).
All variables significant in univariate analyses were
entered to multivariate logistic regression models. A final
model was constructed with the following variables inde-
pendently associated with HIV infection: Yi and other
minority ethnicity (odds ratio [OR], 3.1; 95% confidence
interval [CI], 1.7–5.8; P < 0.001) and total times of shar-
ing injecting equipments in the past (1–9 times versus
none, OR, 2.7; 95% CI 1.2–6.2; P = 0.02; and ≥10 times
versus none, OR, 7.5; 95% CI, 3.2–17.7; P < 0.001) (Table
4).
Discussion
Given the same recruitment methods and participation
eligibility criteria were employed, this study should be
comparable with the first community-based survey in
2002 in estimating HIV prevalence among IDUs in the
study site. HIV prevalence rate in 2004 (17.8%) increases
by over 50% than that in 2002 (11.4%, P = 0.02), which
is consistent with the finding of 3.17 per 100 person-years
seroconversion rate among IDU cohort during years of
2002–2003 [5]. The high HIV prevalence rate and preva-
lent equipment sharing practices are worrisome. Studies
have shown that once HIV prevalence among a high-risk
IDU population reaches 20%, HIV epidemic can become
self-perpetuating and a modest level of risk behaviors may
lead to a substantial rate of infection [6,7]. Furthermore,
Xichang is located in one major drug trafficking route, and
HIV-infected IDUs in Xichang may become a source for
further HIV spread to other geographic areas. China has
initiated harm reduction projects including methadone
maintenance therapy (MMT) and needle exchange pro-
grams. Xichang Center for STD and Leprosy Control is one
of the first 8 clinics in the country to provide pilot MMT
service since early 2004. Limited experiences show a high
drop-out rate of MMT. As China plans to scale up harm
reduction projects and expand MMT service to 1000 clin-
ics across the country within five years [8], research is
urgently needed to improve the efficacy of MMT itself as
well as adding counseling and behavioral intervention
components.
The frequency of sharing injecting equipments is an inde-
pendent risk factor for HIV infection and more times of
sharing is associated with higher risk of infection. Beside
direct sharing of needles or syringes [9-13], indirect shar-
ing of injecting equipments, including cottons, rinse
water, cookers, and front/backloading were also reported
as risk factor for HIV infection in other studies [14,15],
but were not confirmed in our study. "Do not know where
to obtain", "inconvenient to obtain" and "high price of
syringes and needles" were reported as reasons of sharing
equipments, suggesting that provision of clean equip-
ments through needle exchange programs might reduce
risk behaviors among IDUs. Another independent factor
for HIV infection is Yi or other minority ethnicities.
Majority of Yi and other minority people are living in
remote rural areas of Xichang City and are less like to
receive health education and services. Due to relatively
poorer economic status and higher rate of unemploy-
ment, Yi ethnic people are more likely to be involved in
drug smuggling and abuse. Intervention projects should
give high priority to ethnic minority people.
This study has several limitations. First, subjects were not
randomly selected; targeted sampling depends on chain-
referrals (snowball sampling). IDUs who participated inHarm Reduction Journal 2007, 4:6 http://www.harmreductionjournal.com/content/4/1/6
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Table 1: Socio-demographic Factors Associated with HIV seropositivity among IDUs in Xichang City, Sichuan Province, China
Factor N % HIV+ [N] Odds Ratio [95% CI] P-value
Total 314 17.8 [56]
Referred by peers
No 65 15.4 [10] 1.0
Yes 249 18.5 [46] 1.25 [0.59, 2.63] 0.56
Sex
Male 269 19.7 [53] 1.0
Female 45 6.7 [3] 0.29 [0.09, 0.98] 0.03
Age
<29 years 136 21.3 [29] 1.0
≥29 years 178 15.2 [27] 0.66 [0.37, 1.18] 0.16
Ethnicity
Han 192 11.5 [22] 1.0
Other 122 27.9 [34] 2.98 [1.65, 5.41] <0.01
Years of education
≤6 120 21.7 [26] 1.0
>6 194 15.5 [30] 0.66 [0.37, 1.18] 0.16
Employed
Yes 192 19.3 [37] 1.0
No 122 15.6 [19] 0.77 [0.42, 1.42] 0.40
Marital Status
Married or cohabited 83 10.8 [9] 1.0
other 231 20.4 [47] 2.10 [0.98, 4.50] 0.05
Owning a house
No 230 17.0 [39] 1.0
Yes 84 20.2 [17] 1.24 [0.66, 0.34] 0.50
Yearly income in 2003
<1,000 dollars 119 16.0 [19] 1.0
≥1,000 dollars 195 19.0 [37] 1.23 [0.67, 2.26] 0.49
MMT participation
No 259 18.5 [48] 1.0
Yes 55 14.6 [8] 0.75 [0.33, 1.69] 0.48
MMT, methadone maintenance therapy.Harm Reduction Journal 2007, 4:6 http://www.harmreductionjournal.com/content/4/1/6
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the study may differ with those who did not; therefore, the
estimate HIV prevalence may not exactly reflect the true
rate in this study community. However, the sampling
method is same as that in 2002 survey, and HIV preva-
lence rates should be comparable in these two cross-sec-
tional surveys. Second, drug using and sexual behavioral
data were based on self-reports, and recall bias and social
desirability bias are possible. However, the primary out-
come of this study – HIV prevalence – is based on labora-
tory testing. The continued increase of HIV epidemic
among IDUs in Xichang City suggests that comprehensive
interventions for reducing high-risk drug taking and
equipment sharing behaviors are urgently needed.
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Table 2: Drug Use Behavioral Factors Associated with HIV Seropositivity among IDUs in Xichang City, Sichuan Province, China
Factor N % HIV+ [N] Odds Ratio [95% CI] p-value
During of drug injection
<3 years 162 18.5 [30] 1.0
≥3 years 152 17.1 [26] 0.91 [0.51, 1.62] 0.74
Using heroin in the last 3 months
<7 times/week 112 17.9 [20] 1.0
≥7 times/week 202 17.8 [36] 1.00 [0.54, 1.82] 0.99
Using heroin plus other drugs in the last 3 months
<7 times/week 123 14.63 [18] 1.0
≥7 times/week 191 19.9 [38] 1.45 [0.78, 2.68] 0.23
Injecting drugs in the last 3 months
<7 times/week 35 11.4 [4] 1.0
≥7 times/week 279 18.6 [52] 1.78 [0.60, 5.25] 0.29
Total times of sharing injecting equipments in the past
0 times 117 7.7 [9] 1.0
1–9 times 130 16.9 [22] 2.44 [1.08, 5.55]
≥10 times 67 37.3 [25] 7.14 [3.08, 16.56] <0.01
Number of partners sharing injecting equipments in the past
0 persons 117 7.7 [9] 1.0
1–9 persons 157 22.9 [36] 3.57 [1.64, 7.75]
≥10 persons 40 27.5 [11] 4.55 [1.72, 12.03] <0.01
Having new partners sharing injecting equipments in the last 3 months
No 251 14.7 [37] 1.0
Yes 63 30.2 [19] 2.50 [1.32, 4.74] <0.01
Sharing needles and syringes in the last 3 months
No 197 14.7 [29] 1.0
Yes 117 23.1 [27] 1.74 [0.97, 3.11] 0.06
Sharing rinse water in the last 3 months
No 233 15.4 [36] 1.0
Yes 81 24.7 [20] 1.79 [0.97, 3.33] 0.06
Sharing cookers in the last 3 months
No 234 15.4 [36] 1.0
Yes 80 25.0 [20] 1.83 [0.99, 3.40] 0.05
Sharing cottons in the last 3 months
No 301 17.3 [52] 1.0
Yes 13 30.8 [4] 2.13 [0.63, 7.17] 0.24
Front-/back-loading in the last 3 months
No 278 17.6 [49] 1.0
Yes 36 19.4 [7] 1.13 [0.47, 2.72] 0.79Harm Reduction Journal 2007, 4:6 http://www.harmreductionjournal.com/content/4/1/6
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Table 4: Multivariate Logistic Regression Analysis of Factors Associated with HIV Seropositivity
Factor OR [95% CI] p-value
Ethnicity (Minorities versus Han majority) 3.11 [1.67, 5.80] <0.001
Total times of sharing injecting equipments in the last 3 months
1–9 times vs. 0 times 2.70 [1.17, 6.22] 0.02
At least 10 times vs. 0 times 7.45 [3.15, 17.65] <0.001
Table 3: Sexual Behavioral Factors Associated with HIV Seropositivity among IDUs in Xichang City, Sichuan Province, China
Factor N % HIV+ [N] Odds Ratio [95% CI] p-value
Having heterosexual intercourses in the last 6 months
No 130 22.3 [29] 1.0
Yes 184 14.7 [27] 0.60 [0.34, 1.07] 0.08
Having a primary sex partner in the last 6 months
No 218 21.1 [46] 1.0
Yes 96 10.4 [10] 0.43 [0.21, 0.90] 0.02
Having unprotected sex with a primary sex partner in last month
No 252 19.0 [48] 1.0
Yes 62 12.9 [8] 0.63 [0.28, 1.41] 0.26
Having non-primary sex partners in the last 6 months
No 204 18.6 [38] 1.0
Yes 110 16.4 [18] 0.85 [0.46, 1.58] 0.62
Having unprotected sex with non-primary sex partners in last month
No 254 16.1 [41] 1.0
Yes 60 25.0 [15] 1.73 [0.88, 3.40] 0.11
Giving money for sex in the last 6 months
No 250 19.2 [48] 1.0
Yes 64 12.5 [8] 0.60 [0.27, 1.34] 0.21
Receiving money for sex in the last 6 months
No 291 18.2 [53] 1.0
Yes 23 13.0 [3] 0.67 [0.19, 2.35] 0.78
Having new sex partners in the last 6 months
No 238 18.5 [44] 1.0
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